Sphingosine Induces Apoptosis in MKN-28 Human Gastric Cancer Cells in an SDK-Dependent Manner

Takeshi Kanno\textsuperscript{a} Takaaki Nishimoto\textsuperscript{a} Yumiko Fujita\textsuperscript{a,b} Akinobu Gotoh\textsuperscript{c} Takashi Nakano\textsuperscript{b} Tomoyuki Nishizaki\textsuperscript{a}

\textsuperscript{a}Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya; \textsuperscript{b}Department of Thoracic Oncology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya; \textsuperscript{c}Laboratory of Cell and Gene Therapy, Institute for Advanced Medical Sciences, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya

Key Words
Sphingosine • Protein kinase C-\(\delta\) • Sphingosine-dependent protein kinase • Gastric cancer cell • Apoptosis

Abstract

\textbf{Background/Aims:} Evidence has pointed to the role of sphingosine in cellular differentiation, cell growth, and apoptosis. The present study investigated sphingosine-induced apoptosis in human gastric cancer cells. \textbf{Methods:} Well differentiated MKN-28 and poorly differentiated MKN-45 human gastric cancer cells were cultured. MTT assay, TUNEL staining, Western blotting, and assay of caspase-3, -8, and -9 activities were carried out in cells transfected with and without the siRNA to silence the protein kinase C (PKC)-\(\delta\)-targeted gene. \textbf{Results:} Sphingosine induced apoptosis in MKN-28 cells, with the potential much greater than for MKN-45 cells. Transfection with the siRNA to silence the PKC-\(\delta\)-targeted gene (PKC-\(\delta\) siRNA) into MKN-28 cells significantly reduced presence of sphingosine-dependent protein kinase (SDK) in association with reduced PKC-\(\delta\) expression. Sphingosine-induced apoptosis in MKN-28 cells was prevented by transfecting with the PKC-\(\delta\) siRNA. Sphingosine promoted SDK production from PKC-\(\delta\) and increased phosphorylated 14-3-3 protein for MKN-28 cells, but such effects were not found with MKN-45 cells. Moreover, sphingosine perturbed mitochondrial membrane potentials and activated caspase-3 and caspase-9 in MKN-28 cells, which were also inhibited by transfecting with the PKC-\(\delta\) siRNA. \textbf{Conclusion:} The results of the present study indicate that sphingosine induces apoptosis in well differentiated MKN-28 human gastric cancer cells by increasing SDK production from PKC-\(\delta\), to phosphorylate 14-3-3 protein, thereby causing disruption of mitochondrial membrane potentials and activating caspase-9 followed by the effector caspase-3.
Introduction

Sphingolipids such as ceramide, ceramide 1-phosphate, sphingosine, and sphingosine 1-phosphate (S1P) are implicated in the regulation of cellular differentiation, cell growth, and apoptosis. Mounting evidence has pointed to the role of ceramide in apoptosis via diverse signaling pathways. Sphingosine, that is produced from ceramidase-catalyzed cleavage of fatty acids from ceramide, also participates in apoptotic cell death. Sphingosine induces apoptosis in rhabdomyosarcoma cells through mitochondrial Bax and the ensuing caspase activation [1]. Sphingosine, alternatively, induces apoptosis in mouse BALB/c 3T3 clone A31 cells via an SDK pathway [2]. Furthermore, sphingosine induces apoptosis in hippocampal neurons and astrocytes by activating caspase-3/-9 via an SDK/14-3-3 protein/Bax/cytochrome c pathway [3]. SDK is a protein kinase that is produced through proteolytic processing of PKC-δ and it is activated by binding sphingosine [2]. SDK phosphorylates 14-3-3 protein as a target [4, 5], which could dissociate Bax from a complex with 14-3-3 protein, to induce a mitochondria-dependent apoptosis.

The present study aimed at understanding sphingosine-induced apoptosis in human gastric cancer cells and the underlying pathway. We show here that sphingosine induces apoptosis in well differentiated MKN-28 human gastric cancer cells by activating caspase-3/-9 in concert with mitochondrial damage in an SDK-dependent manner.

Materials and Methods

Cell cultures

MKN-28 cells, a well differentiated human gastric cancer cell line, and MKN-45 cells, a poorly differentiated human gastric cancer cell line, were grown in a RPMI1640 solution (Sigma, St. Louis, MO, USA) supplemented with 10% (v/v) fetal bovine serum, penicillin (final concentration, 100 U/ml), and streptomycin (final concentration, 0.1 mg/ml) in a humidified atmosphere of 5% CO₂ and 95% air at 37 °C.

Assay of cell viability

Cell viability was assayed by the method using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) as described previously [3]. MTT-reactive cells were quantified at an absorbance of 570 nm using a micro-plate reader (SPECTRAMax PLUS384, Molecular Devices, Sunnyvale, CA, USA). Various concentrations of sphingosine were dissolved in ethanol and further, diluted at 1:1000 with culture medium containing MTT when applied. We have confirmed that 0.1% (v/v) ethanol has no effect on cell viability for MKN-28 and MKN-45 cells.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining

TUNEL staining was performed to detect in situ DNA fragmentation as a marker of apoptosis using an In Situ Apoptosis Detection Kit (Takara Bio, Otsu, Japan). Briefly, fixed and permeabilized cells were reacted with terminal deoxynucleotidyl transferase and fluorescein isothiocyanate (FITC)-deoxyuridine triphosphate for 90 min at 37 °C. FITC signals were visualized with a confocal scanning laser microscope (LSM 510, Carl Zeiss Co., Ltd., Oberkochen, Germany).

Monitoring of mitochondrial membrane potentials

Mitochondrial membrane potentials were measured using a DePsipher™ kit. Cells untreated and treated with sphingosine were incubated in a DePsipher™ solution at 37 °C for 20 min. Then, cells were washed with 1 ml of a reaction buffer containing a stabilizer solution. The fluorescent signals were observed with a laser scanning microscope (LSM 510) equipped with an epifluorescence device using a fluorescein long-pass filter (fluorescein and rhodamine) at an absorbance of 590 nm for red aggregations and at an absorbance of 530 nm for green aggregations.
Enzymatic assay of caspase-3, -8, and -9 activities

Caspase activity was measured using a caspase fluorometric assay kit (Ac-Asp-Glu-Val-Asp-MCA for a caspase-3 substrate peptide; Ac-Ile-Glu-Thr-Asp-MCA for a caspase-8 substrate peptide; and Ac-Leu-Glu-His-Asp-MCA for a caspase-9 substrate peptide) as previously described [3]. Briefly, cells were harvested before and after treatment with sphingosine, and then centrifuged at 3,000 rpm for 5 min at 4 °C. The pellet was incubated on ice in cell lysis buffer for 10 min, and reacted with the fluorescently labeled tetrapeptide at 37 °C for 2 h. The fluorescence was measured at an excitation of wavelength of 380 nm and an emission wavelength of 460 nm with a fluorometer (Fluorescence Spectrometer, F-4500, HITACHI, Tokyo, Japan).

Construction and transfection of siRNA

The siRNA to silence PKC-δ-targeted gene (PKC-δ siRNA) and the negative control siRNA (NC siRNA) were obtained from BONAC (Fukuoka, Japan). The PKC-δ siRNA and the NC siRNA were reverse-transfected into cells using a Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA). Cells were used for experiments 48 h after transfection.

Western blotting

Cells were lysed with 1% (w/v) sodium dodecyl sulfate (SDS). Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using a TGX gel (BioRad, Hercules, CA, USA) and then transferred to polyvinylidene difluoride membranes. Blotting membranes were blocked with TBS-T [150 mM NaCl, 0.1% (v/v) Tween20 and 20 mM Tris, pH 7.5] containing 5% (w/v) bovine serum albumin and
subsequently incubated with an anti-PKC-δ antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), an anti-14-3-3 protein antibody (Abgent, San Diego, CA, USA), an anti-phospho-14-3-3 protein antibody (Abcam, Cambridge, MA, USA), that detects at phospho-Ser58 on 14-3-3γ, η, and ζ, or an anti-β-actin antibody (Sigma). After washing, membranes were reacted with a horseradish peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG antibody. Immunoreactivity was detected with an ECL kit (GE Healthcare, Piscataway, NJ, USA) and visualized using a chemiluminescence detection system (GE Healthcare). Immunoblotting for SDK was carried out using an anti-PKC-δ antibody (Santa Cruz Biotechnology). Protein concentrations for each sample were determined with a BCA protein assay kit (Pierce, Rockford, IL, USA).

**Statistical analysis**

Statistical analysis was carried out using unpaired t-test and Dunnett’s test.

**Results**

**Sphingosine induces MKN-28 cell apoptosis in an SDK-dependent manner**

For MKN-28 cells, sphingosine reduced cell viability at concentrations more than 10 µM, reaching 30% of untreated basal levels at 100 µM (Fig. 1A). In contrast, sphingosine reduced MKN-45 cell viability to much lesser extent (Fig. 1A). For MKN-28 cells, sphingosine (100 µM) increased TUNEL-positive cells to 75% of total cells from 5% before treatment (Fig. 2). This accounts for sphingosine-induced apoptosis in MKN-28 cells. Sphingosine is metabolized into S1P through its phosphorylation due to sphingosine kinase. S1P at concentrations ranging from 1 to 100 µM had no effect on cell viability for MKN-28 and MKN-45 cells (data not shown). This indicates that the sphingosine effect obtained here is not caused by its metabolite S1P.

Sphingosine (100 µM)-induced reduction in MKN-28 cell viability was not affected by GF109203X (100 nM), an inhibitor of PKC (Fig. 1B). This suggests that sphingosine induces MKN-28 cell apoptosis via a pathway independent of PKC activation.
Sphingosine is recognized to activate SDK, that is produced through proteolytic processing of PKC-δ [2]. To examine the implication of PKC-δ/SDK in sphingosine-induced MKN-28 cell apoptosis, we have constructed the PKC-δ siRNA. Expression of PKC-δ protein was significantly decreased in MKN-28 cells transfected with the PKC-δ siRNA as compared with the expression for cells transfected with the NC siRNA (Fig. 1C), which confirms PKC-δ knocking-down. Notably, SDK presence was also suppressed by transfecting with the PKC-δ siRNA (Fig. 1C). Sphingosine-induced reduction in MKN-28 cell viability or an increase in TUNEL-positive cells was significantly prevented by transfecting with the PKC-δ siRNA (Fig. 1D, 2). This, in the light of the fact that the sphingosine effect on MKN-28 cell viability was independent of PKC activation, suggests that sphingosine induces MKN-28 cell apoptosis by activating SDK.

Sphingosine increases SDK production from PKC-δ and phosphorylates 14-3-3 protein in MKN-28 cells

Sphingosine (100 μM) increased the amount of SDK in parallel with decreased PKC-δ in a treatment time (0-40 min)-dependent manner for MKN-28 cells (Fig. 3A). In contrast,
neither increase in SDK nor decrease in PKC-δ was obtained with MKN-45 cells (Fig. 3B). These results indicate that sphingosine promotes SDK production through proteolytic processing of PKC-δ in MKN-28 cells, but not MKN-45 cells.

14-3-3 protein is a target of SDK phosphorylation [4, 5]. Sphingosine (100 µM) increased phosphorylated 14-3-3 protein ζ in a treatment time (0-40 min)-dependent manner for

---

Fig. 5. Sphingosine-induced disruption of mitochondrial membrane potentials in gastric cancer cells. Mitochondrial membrane potentials were monitored in MKN-28 cells transfected with the NC siRNA (NC) or the PKC-δ siRNA (PKC-δ KD) before and after 1-h treatment with sphingosine (100 µM). Typical fluorescent images are shown in the upper panel. Bars, 50 µm. Red and green fluorescent intensities in the area (0.4 mm x 0.4 mm) selected at random were measured using ImageJ (Bethesda, MD, USA), and red fluorescent intensities at an absorbance of 590 nm for cells untreated with sphingosine or green fluorescent intensities at an absorbance of 530 nm for cells treated with sphingosine were regarded as 1. In the graph, each column represents the mean (± SEM) intensity (n=4 independent experiments). P value, Dunnett’s test.

Fig. 6. Sphingosine-induced activation of caspase-3/-9 in MKN-28 cells. Activities of caspase-3, -8, and -9 were enzymatically assayed in MKN-28 cells transfected with the NC siRNA (NC) or the PKC-δ siRNA (PKC-δ KD) before and after treatment with sphingosine (100 µM). In the graphs, each point represents the mean (± SEM) ratio against basal caspase activities (before treatment with sphingosine)(n=4 independent experiments).
MKN-28 cells (Fig. 4A), but such effect was not found with MKN-45 cells (Fig. 4B). This suggests that sphingosine binds to and activates SDK, to phosphorylate 14-3-3 protein.

**Sphingosine disrupts mitochondrial membrane potentials, activates caspase-3/-9 in MKN-28 cells in an SDK-dependent manner**

Phosphorylated 14-3-3 protein could cause disruption of mitochondrial membrane potentials by dissociating Bax. To address this point, mitochondrial membrane potentials were monitored using DePsipher™, a mitochondrial activity marker. DePsipher™ is detected as an orange-red fluorescence at an absorbance of 590 nm for normal mitochondrial membrane potentials, but in case of the disruption the dye turns into green fluorescence at an absorbance of 530 nm. For MKN-28 cells, the mitochondria exhibited orange-red fluorescent signals alone without green fluorescent signals (Fig. 5). Sphingosine (100 µM) accumulated green fluorescent signals with weaker orange-red fluorescent signals (Fig. 5). This confirms that sphingosine disrupts mitochondrial membrane potentials in MKN-28 cells. Sphingosine (100 µM)-induced disruption of mitochondrial membrane potentials was significantly inhibited by transfecting with the PKC-δ siRNA (Fig. 5). Collectively, these results indicate that sphingosine disrupts mitochondrial membrane potentials in an SDK-dependent manner in MKN-28 cells.

Disruption of mitochondrial membrane potentials could allow cytochrome c efflux from the mitochondria, to form a complex with Apaf-1/dATP, causing activation of caspase-9 and the effector caspase-3. To answer this question, we enzymatically assayed activities of caspase-3, -8, and -9. Expectedly, sphingosine (100 µM) activated caspase-3 and -9, but not caspase-8, for MKN-28 cells, with the peak 1 h after treatment (Fig. 6). Sphingosine (100 µM)-induced activation of caspase-3 and -9 was clearly prevented by transfecting with the PKC-δ siRNA (Fig. 6). Sphingosine, thus, appears to activate caspase-9 followed by caspase-3 in concert with damaged mitochondria in an SDK-dependent manner.

**Discussion**

The present study examined the apoptotic effect of sphingosine on two types of human gastric cancer cell lines such as well differentiated MKN-28 cells and poorly differentiated MKN-45 cells. Sphingosine induced apoptosis in MKN-28 cells, with the potential much greater than for MKN-45 cells. Interestingly, sphingosine has the potential to inhibit PKC-δ [6]. This raises the possibility that sphingosine might induce apoptosis in MKN-28 cells by inhibiting PKC-δ. The sphingosine effect here, however, was not affected by GF109203X, that inhibits PKCs including PKC-δ by binding to the ATP binding site on PKCs. This would rule out sphingosine-induced MKN-28 cell apoptosis due to PKC-δ inhibition. In contrast, the sphingosine effect was prevented by transfecting with the PKC-δ siRNA, to decrease presence of SDK in association with decreased PKC-δ expression. This suggests that SDK, but not PKC-δ, is implicated in sphingosine-induced MKN-28 cell apoptosis.

Sphingosine increased SDK in parallel with decreased PKC-δ for MKN-28 cells, but such effect was not found with MKN-45 cells. SDK is produced through proteolytic processing of PKC-δ [2]. Sphingosine, accordingly, is likely to promote SDK production from PKC-δ and activate SDK in MKN-28 cells. SDK is recognized to specifically phosphorylate 14-3-3 protein [4, 5]. In the present study, sphingosine increased phosphorylated 14-3-3 protein ζ in MKN-28 cells, but not in MKN-45 cells. 14-3-3 protein inhibits apoptosis by capturing Bax [7]. Conversely, phosphorylated 14-3-3 protein dissociates Bax from a complex with 14-3-3 protein and in turn, free Bax moves towards the mitochondria and makes holes to disrupt mitochondrial membrane potentials, leading to mitochondrial apoptosis [8-11]. Sphingosine here disrupted mitochondrial membrane potentials in MKN-28 cells, and the effect was inhibited by transfecting with the PKC-δ siRNA. This suggests that sphingosine activates SDK, to phosphorylate 14-3-3 protein and disrupt mitochondrial membrane potentials in MKN-28 cells.
Mitochondrial damage allows cytochrome c efflux from the mitochondria, which forms a complex with Apaf-1/dATP to activate caspase-9 and the effector caspase-3. In the present study, sphingosine significantly activated caspase-3 and -9, but not caspase-8, in MKN-28 cells, and the activation was abolished by transfecting with the PKC-δ siRNA. This provides evidence that sphingosine activates caspase-9 and the effector caspase-3 in an SDK-dependent manner for MKN-28 cells. Overall, these results lead to a conclusion that sphingosine promotes SDK production from PKC-δ and activates SDK, to phosphorylate 14-3-3 protein, thereby dissociating Bax from a complex with 14-3-3 protein and consequently disrupting mitochondrial membrane potentials, to activate caspase-9 followed by the effector caspase-3, responsible for MKN-28 cell apoptosis. Sphingosine induced apoptosis in MKN-28 cells, with the potential much higher than for MKN-45 cells, and SDK for MKN-28 cells was produced more than for MKN-45 cells. This suggests that the potential for the apoptotic action of sphingosine may depend on SDK production.

In conclusion, the results of the present study show that sphingosine induces apoptosis in well differentiated MKN-28 human gastric cancer cells in an SDK-dependent manner.

References


